Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cancer Genetics Inc announces new data for diagnosis and prediction of kidney cancer outcomes using its genomic test


Monday, 24 Feb 2014 07:30am EST 

Cancer Genetics Inc:Announces new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer will be presented at the annual United States & Canadian Academy of Pathology (USCAP) meeting on March 3rd in San Diego, CA.The new data was generated as part of a collaborative study conducted with the Cleveland Clinic in which 191 pathology specimens from renal cancer patients were provided and analyzed using the UroGenRA-Kidney test. 

Company Quote

10.8
-0.3 -2.70%
12:37pm EDT